

Profile of Childhood Cancers From Hospital-Based Cancer Registries in India, 2012-19

Gauri Kapoor,¹ Ramandeep Singh Arora,² Venkatraman Radhakrishnan,³ Anita Nath,⁴
Payal Malhotra,¹ Sunu Lazar Cyriac,⁵ Gangadharan VP,⁶ Sadashivudu G,⁷
Thilagavathi Ramamoorthy,⁴ Sudarshan KL,⁴ Prashant Mathur⁴

¹Department of Pediatric Hematology Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi.

²Department of Pediatric Oncology, Max Super Speciality Hospital, New Delhi.

³Department of Medical Oncology, Adyar Cancer Institute, Chennai, Tamil Nadu.

⁴ICMR - National Centre for Disease Informatics and Research, Indian Council of Medical Research, Bengaluru, Karnataka.

⁵Department of Medical Oncology and Hematology, Amala Institute of Medical Sciences, Thrissur, Kerala.

⁶Department of Medical and Pediatric Oncology, Lakeshore Hospital, Kochi, Kerala.

⁷Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana.

ABSTRACT

Objective: To describe the clinical pattern of childhood and adolescent cancers across India using hospital-based data in the National Cancer Registry Program.

Methods: Records of 60720 cancer cases in the 0-19 year age group for the period 2012-2019 from 96 hospital-based cancer registries were reviewed. Childhood cancers were classified based on the International Classification of Childhood Cancer (ICCC). Descriptive analysis was used to examine the distribution of cancer by five-year age groups, sex and ICCC diagnostic groups and subgroups. Data were analysed using IBM SPSS software and visualised using R software.

Results: 3.2% and 4.6% of all cancer cases in India were among children in the 0-14 year and 0-19 year age groups respectively. The male-to-female ratio for all cancers was 1.72 for 0-14 years and 1.73 for 0-19 years. The four leading groups of cancers among 0-14 year olds were leukemia (40%), lymphoma (12%), central nervous system tumor (11%) and bone cancer (8%). The four leading cancers among the 0-19 year age group were leukemia (36%), lymphoma (12%), bone (11%) and central nervous system tumor (10%).

Conclusion: Cancers in the 0-14 and 0-19 age groups accounted for a considerable proportion of all cancers with significant male preponderance. Such information helps to fine-tune research and planning strategies.

Keywords: Adolescent, Cancer, Child, India, Registries

INTRODUCTION

Strategies to control cancer start with understanding the occurrence of cancer and its distribution. Knowing how many patients develop, are treated for, and ultimately survive cancer is vital data for evidence-based resource allocation. Cancer registries collect accurate and complete cancer data that can be used for cancer control and epidemiological research, public health program planning, and patient care improvement. In childhood cancer, such information helps to understand disease etiology, improve access to care, plan investments in service delivery,

advocate for resource allocation, and measure the quality of different health system components involved [1]. Ultimately, all of these activities reduce the burden of cancer.

Data from the National Cancer Registry Programme (NCRP), established by the Indian Council of Medical Research (ICMR) in 1981, is generated through a network of 38 Population-Based Cancer Registries (PBCRs) and 246 Hospital-Based Cancer Registries (HBCRs). The recent NCRP report of 96 HBCRs has captured data on the topography (site), clinical staging, histology, site of pediatric cancers and treatment details [2].

In India, previous publications on the distribution of childhood cancer in India have been restricted to particular geographical regions [3,4] and have generally excluded adolescents with cancer. Globally, there is a relative lack of representation on registry-level information on childhood

Correspondence to: Dr. Prashant Mathur, National Centre for Disease Informatics and Research, Indian Council of Medical Research, Bengaluru, Karnataka.

director-ncdir@icmr.gov.in

Received: Mar 29, 2023; Initial review: Apr 30, 2023;

Accepted: Nov 10, 2023.

and adolescent cancer from low and middle-income countries (LMIC), which account for more than 80% of the burden of children with cancer [5]. The present paper offers an opportunity to address this gap and describes the clinical pattern of childhood and adolescent cancers across India using hospital-based data in the NCRP.

METHODS

The present study was a descriptive cross-sectional analysis based on eight-year data (2012 to 2019) on childhood cancers from 96 HBCRs [2]. These HBCRs are located in specialised oncology centres /general or multi-speciality hospitals (public and private) covering urban and rural areas of the country. Data collection was done using a standardized common core form consisting of patient identifying and socio-demographic information, details of diagnosis, clinical extent of disease, and broad type of treatment.

Topography (site) was coded according to the International Classification of Diseases-10th Revision (ICD-10) and morphology by the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [6,7]. Only tumors with malignant behaviour were reported.

Childhood cancers were defined as cancers in two broad categories: 0-14 and 0-19 years that were classified based on the International Classification of Childhood Cancer (ICCC), 3rd edition [8].

Statistical analysis: Descriptive analysis was used to examine the distribution of cancer by five-year age groups, sex and ICCC diagnostic groups and subgroups. Data were analyzed using SPSS software (Version 27.0; IBM Corp, Armonk, NY, USA) and visualized using R software.

RESULTS

Among the 1332207 cancer cases in all sites that were registered at 96 HBCRs during 2012-19, 3.2% (42527) were among children in the 0-14 year age group, 1.4%

(18193) were adolescents in the 15-19 year age group, and the cancers in the combined group (0-19 year) constituted 4.6% of all cases (**Table I**). The male-to-female ratio was 1.72 in the 0-14 and 1.73 in the 0-19 age groups.

The four leading groups of cancers among 0-14 years were leukemia (40%), lymphoma (12%), central nervous system (CNS) tumor (11%) and bone cancer (8%) (**Fig. 1**). The distribution among boys and girls was broadly similar, except that the proportion of lymphoma was higher in boys (15%) than in girls (7%).

The four leading cancers among the 0-19 year age group were leukemia (36%), lymphoma (12%), bone (11%), CNS (10%) and soft tissue cancers (7%), as seen in **Fig. 1**. Lymphomas were more common among males than females (15% vs 8%). However, the reverse was observed for carcinomas (5% vs 7%) and germ cells (2% vs 4%).

Leukemias constituted the most prominent group across all ages, constituting half of all cancers in the 0-4 year (42.1%) and the 5-9 year age group (42.5%), as described in **Table II**. This was followed by lymphomas (12.3%) that had the most significant proportion in the 5-9 year age group (15.7%), of which Hodgkin lymphoma was the most typical (7.9%). Malignant bone tumors (10.7%) were the third largest group overall and the second most common cancer group in the 10-14 year (16.0%) and 15-19 year age group (17.9%), mainly constituted by osteosarcoma and Ewing sarcoma. Rhabdomyosarcoma, retinoblastoma, Wilm's tumor and neuroblastoma were all seen primarily in the 0-4 year age group. CNS tumors had an overall proportion of 9.6% in the 0-19 year age group, with the highest proportion between 5-9 years, and the most significant pathological type was primitive neuroectodermal tumors (PNET).

DISCUSSION

Based on NCRP data, the present study analyzed 60720 cancer cases (0-19 years) from 96 HBCRs, over eight years. With a younger population pyramid, it is not

Table I Childhood Cancers Relative to Cancers Across All Ages: Data from 96 Hospital-Based Cancer Registries, India, 2012-2019

| Age (y) | Boys (n = 705395) | | Girls (n = 626812) | | Total (n = 1332207) | |
|---------|-------------------|------------------|--------------------|------------------|---------------------|------------------|
| | n | % of all cancers | n | % of all cancers | n | % of all cancers |
| 0-4 | 9320 | 1.3 | 5764 | 0.9 | 15084 | 1.1 |
| 5-9 | 8883 | 1.3 | 4728 | 0.8 | 13611 | 1.0 |
| 10-14 | 8668 | 1.2 | 5164 | 0.8 | 13832 | 1.0 |
| 15-19 | 11589 | 1.6 | 6604 | 1.1 | 18193 | 1.4 |
| 0-14 | 26871 | 3.8 | 15656 | 2.5 | 42527 | 3.2 |
| 0-19 | 38460 | 5.5 | 22260 | 3.6 | 60720 | 4.6 |




Fig. 1 Relative contribution of the 12 diagnostic groups of childhood cancer in (0-14) and (0-19) years.

surprising that children 0-14 and adolescents 0-19 years of age represent 3.2% and 4.6% of the total cancers reported at hospitals. In contrast, this proportion is 1-2% in countries with high human development index [9].

Leukemias comprised nearly half of all cancers in the 0-14 and 0-19 age groups, which is in accordance with findings from other studies [10,11]. Lymphoid leukemia, including acute lymphoblastic leukemia (ALL), comprised most leukemia types. Similar to the high male-to-female ratio of cancer cases observed in our study, sex disparity in cancer registration has previously been described in LMICs, especially those with low female education rates, wherein girls with cancer often go undiagnosed [12]. The higher sex differential in India could be ascribed to social determinants such as gender discrimination and skewed sex ratio due to male birth preferences that outnumber female births in India [13]. The proportion of leukemias and bone cancer in the 0-14 and the 0-19 year age group was higher than population-based data from India in the IICC paper by Steliarova-Foucher et al in which reported proportions of leukemia were 38.4% and 34.1% and for bone cancer, 5.6% and 7.6% in the 0-14 and 0-19 year age groups respectively, which could be accounted for by differences in the hospital

referral practices [14]. Furthermore, the proportional distribution of CNS tumors reported internationally (17-26%) is remarkably higher than that observed in the present analysis (11% in 0-14 and 10% in 0-19 age group). One explanation for this wide gap is that CNS tumors are possibly treated in neurosurgical centres in multi-speciality (general) hospitals rather than dedicated cancer centres in India. Another explanation could be that currently, the NCRP only registers “malignant” (defined as World Health Organization Grade 3 and 4) CNS tumors.

The proportion of Non-Hodgkin lymphomas (NHL) increased with rising age groups in our analysis, supporting evidence that NHL increases steadily with age and more so in males, which may result from innate sex differences in susceptibility and HIV [15]. The higher proportion of malignant bone tumors in girls is probably due to earlier skeletal maturity. The data from the Indian HBCRs not only gives us valuable information on the distribution of cancer in children and adolescents but also supplements the PBCRs, allowing estimates of incidence and longitudinal trends. Cancers in the 0-19 age group accounted for a considerable proportion of all cancers, with significant male preponderance.

Table II Number and Proportion of Specific Types of Cancers (ICCC-3 Classification) by 5 Year Age Groups, India, 2012-2019

| Cancer classification | 0-4y | | 5-9y | | 10-14y | | 15-19y | | Total (0-14y) | | Total (0-19y) | |
|---|------|------|------|------|--------|------|--------|------|---------------|------|---------------|------|
| | n | % | n | % | n | % | n | % | n | % | n | % |
| Leukemia | 6354 | 42.1 | 5790 | 42.5 | 4843 | 35.0 | 4963 | 27.3 | 16987 | 39.9 | 21950 | 36.1 |
| Lymphoid leukemia | 4871 | 32.3 | 4227 | 31.1 | 3037 | 22.0 | 2649 | 14.6 | 12135 | 28.5 | 14784 | 24.3 |
| Acute non-lymphocytic leukemia | 897 | 5.9 | 950 | 7.0 | 1132 | 8.2 | 1249 | 6.9 | 2979 | 7.0 | 4228 | 7.0 |
| Chronic myeloid leukemia | 54 | 0.4 | 133 | 1.0 | 279 | 2.0 | 539 | 3.0 | 466 | 1.1 | 1005 | 1.7 |
| Other specified leukemia | 55 | 0.4 | 29 | 0.2 | 24 | 0.2 | 38 | 0.2 | 108 | 0.3 | 146 | 0.2 |
| Unspecified leukemia | 477 | 3.2 | 451 | 3.3 | 371 | 2.7 | 488 | 2.7 | 1299 | 3.1 | 1787 | 2.9 |
| Lymphomas and reticuloendothelial neoplasm | 762 | 5.1 | 2134 | 15.7 | 2089 | 15.1 | 2502 | 13.8 | 4985 | 11.7 | 7487 | 12.3 |
| Hodgkin lymphoma | 170 | 1.1 | 1070 | 7.9 | 943 | 6.8 | 1163 | 6.4 | 2183 | 5.1 | 3346 | 5.5 |
| Non-Hodgkin lymphoma | 315 | 2.1 | 673 | 4.9 | 869 | 6.3 | 1132 | 6.2 | 1857 | 4.4 | 2989 | 4.9 |
| Burkitt's lymphoma | 140 | 0.9 | 273 | 2.0 | 138 | 1.0 | 69 | 0.4 | 551 | 1.3 | 620 | 1.0 |
| Miscellaneous lymphoreticular neoplasms | 108 | 0.7 | 35 | 0.3 | 33 | 0.2 | 31 | 0.2 | 176 | 0.4 | 207 | 0.3 |
| Unspecified lymphomas | 29 | 0.2 | 83 | 0.6 | 106 | 0.8 | 107 | 0.6 | 218 | 0.5 | 325 | 0.5 |
| Central Nervous System and miscellaneous intracranial and intraspinal neoplasms | 1047 | 6.9 | 1907 | 14.0 | 1604 | 11.6 | 1249 | 6.9 | 4558 | 10.7 | 5807 | 9.6 |
| Ependymoma | 233 | 1.5 | 262 | 1.9 | 173 | 1.3 | 122 | 0.7 | 668 | 1.6 | 790 | 1.3 |
| Astrocytoma | 138 | 0.9 | 369 | 2.7 | 461 | 3.3 | 512 | 2.8 | 968 | 2.3 | 1480 | 2.4 |
| Primitive neuroectodermal tumors | 434 | 2.9 | 706 | 5.2 | 562 | 4.1 | 271 | 1.5 | 1702 | 4.0 | 1973 | 3.2 |
| Other gliomas | 131 | 0.9 | 424 | 3.1 | 293 | 2.1 | 244 | 1.3 | 848 | 2.0 | 1092 | 1.8 |
| Other specified intracranial and intraspinal neoplasms | 42 | 0.3 | 39 | 0.3 | 51 | 0.4 | 52 | 0.3 | 132 | 0.3 | 184 | 0.3 |
| Unspecified intracranial and intraspinal neoplasms | 69 | 0.5 | 107 | 0.8 | 64 | 0.5 | 48 | 0.3 | 240 | 0.6 | 288 | 0.5 |
| Sympathetic Nervous System tumors | 1139 | 7.6 | 407 | 3.0 | 116 | 0.8 | 72 | 0.4 | 1662 | 3.9 | 1734 | 2.9 |
| Neuroblastoma and ganglioneuroblastoma | 1128 | 7.5 | 395 | 2.9 | 100 | 0.7 | 45 | 0.2 | 1623 | 3.8 | 1668 | 2.7 |
| Other SNS tumors | 11 | 0.1 | 12 | 0.1 | 16 | 0.1 | 27 | 0.1 | 39 | 0.1 | 66 | 0.1 |
| Retinoblastoma | 1284 | 8.5 | 219 | 1.6 | 29 | 0.2 | 3 | <0.1 | 1532 | 3.6 | 1535 | 2.5 |
| Renal tumors | 1279 | 8.5 | 435 | 3.2 | 103 | 0.7 | 74 | 0.4 | 1817 | 4.3 | 1891 | 3.1 |
| Wilm's tumor, rhabdoid and clear cell sarcoma | 1260 | 8.4 | 410 | 3.0 | 73 | 0.5 | 24 | 0.1 | 1743 | 4.1 | 1767 | 2.9 |
| Renal carcinoma | 19 | 0.1 | 25 | 0.2 | 30 | 0.2 | 50 | 0.3 | 74 | 0.2 | 124 | 0.2 |
| Hepatic tumors | 475 | 3.1 | 108 | 0.8 | 64 | 0.5 | 80 | 0.4 | 647 | 1.5 | 727 | 1.2 |
| Hepatoblastoma | 425 | 2.8 | 77 | 0.6 | 26 | 0.2 | 3 | <0.1 | 528 | 1.2 | 531 | 0.9 |
| Hepatic carcinoma | 29 | 0.2 | 24 | 0.2 | 36 | 0.3 | 70 | 0.4 | 89 | 0.2 | 159 | 0.3 |

Contd...

Continued from pre-page

| 0-4y | 5-9y | 10-14y | 15-19y | Total (0-14y) | Total (0-19y) | | | | | | | |
|---|-------|--------|--------|---------------|---------------|-------|-------|-------|-------|-------|-------|-------|
| Unspecified malignant hepatic tumors | 21 | 0.1 | 7 | 0.1 | 2 | <0.1 | 7 | <0.1 | 30 | 0.1 | 37 | 0.1 |
| Malignant bone tumors | 216 | 1.4 | 822 | 6.0 | 2212 | 16.0 | 3253 | 17.9 | 3250 | 7.6 | 6503 | 10.7 |
| Osteosarcoma | 24 | 0.2 | 314 | 2.3 | 1285 | 9.3 | 2120 | 11.7 | 1623 | 3.8 | 3743 | 6.2 |
| Chondrosarcoma | 2 | 0.0 | 7 | 0.1 | 43 | 0.3 | 86 | 0.5 | 52 | 0.1 | 138 | 0.2 |
| Ewing sarcoma | 140 | 0.9 | 453 | 3.3 | 757 | 5.5 | 804 | 4.4 | 1350 | 3.2 | 2154 | 3.5 |
| Other specified malignant bone tumors | 24 | 0.2 | 13 | 0.1 | 41 | 0.3 | 123 | 0.7 | 78 | 0.2 | 201 | 0.3 |
| Unspecified malignant bone tumors | 26 | 0.2 | 35 | 0.3 | 86 | 0.6 | 120 | 0.7 | 147 | 0.3 | 267 | 0.4 |
| Soft-tissue sarcomas | 1059 | 7.0 | 839 | 6.2 | 1022 | 7.4 | 1532 | 8.4 | 2920 | 6.9 | 4452 | 7.3 |
| Rhabdomyosarcoma and embryonal sarcomas | 650 | 4.3 | 398 | 2.9 | 272 | 2.0 | 267 | 1.5 | 1320 | 3.1 | 1587 | 2.6 |
| Fibrosarcoma, neurofibrosarcoma and other fibromatous neoplasms | 51 | 0.3 | 44 | 0.3 | 75 | 0.5 | 138 | 0.8 | 170 | 0.4 | 308 | 0.5 |
| Kaposi sarcoma | 0 | 0.0 | 0 | 0.0 | 3 | <0.1 | 3 | <0.1 | 3 | <0.1 | 6 | <0.1 |
| Other specified soft tissue sarcoma | 257 | 1.7 | 297 | 2.2 | 512 | 3.7 | 814 | 4.5 | 1066 | 2.5 | 1880 | 3.1 |
| Unspecified soft tissue sarcoma | 101 | 0.7 | 100 | 0.7 | 160 | 1.2 | 310 | 1.7 | 361 | 0.8 | 671 | 1.1 |
| Germ-cell trophoblastic and other gonadal neoplasms | 528 | 3.5 | 150 | 1.1 | 299 | 2.2 | 779 | 4.3 | 977 | 2.3 | 1756 | 2.9 |
| Intracranial and intraspinal GC tumors | 23 | 0.2 | 28 | 0.2 | 60 | 0.4 | 53 | 0.3 | 111 | 0.3 | 164 | 0.3 |
| Other and unspecified non-gonadal GC tumors | 232 | 1.5 | 20 | 0.1 | 33 | 0.2 | 119 | 0.7 | 285 | 0.7 | 404 | 0.7 |
| Gonadal germ cell tumors | 264 | 1.8 | 89 | 0.7 | 179 | 1.3 | 503 | 2.8 | 532 | 1.3 | 1035 | 1.7 |
| Gonadal carcinomas | 5 | <0.1 | 5 | <0.1 | 15 | 0.1 | 65 | 0.4 | 25 | 0.1 | 90 | 0.1 |
| Other and unspecified gonadal tumors | 4 | 0.0 | 8 | 0.1 | 12 | 0.1 | 39 | 0.2 | 24 | 0.1 | 63 | 0.1 |
| Carcinoma and other malignant epithelial neoplasms | 211 | 1.4 | 331 | 2.4 | 774 | 5.6 | 2251 | 12.4 | 1316 | 3.1 | 3567 | 5.9 |
| Adrenocortical carcinoma | 26 | 0.2 | 17 | 0.1 | 13 | 0.1 | 10 | 0.1 | 56 | 0.1 | 66 | 0.1 |
| Thyroid carcinoma | 3 | <0.1 | 8 | 0.1 | 33 | 0.2 | 159 | 0.9 | 44 | 0.1 | 203 | 0.3 |
| Nasopharyngeal carcinoma | 0 | 0.0 | 26 | 0.2 | 181 | 1.3 | 323 | 1.8 | 207 | 0.5 | 530 | 0.9 |
| Malignant melanoma | 11 | 0.1 | 9 | 0.1 | 7 | 0.1 | 31 | 0.2 | 27 | 0.1 | 58 | 0.1 |
| Skin carcinoma | 8 | 0.1 | 27 | 0.2 | 27 | 0.2 | 63 | 0.3 | 62 | 0.1 | 125 | 0.2 |
| Other and unspecified carcinoma | 163 | 1.1 | 244 | 1.8 | 513 | 3.7 | 1665 | 9.2 | 920 | 2.2 | 2585 | 4.3 |
| Other and unspecified malignant neoplasms | 389 | 2.6 | 180 | 1.3 | 188 | 1.4 | 383 | 2.1 | 757 | 1.8 | 1140 | 1.9 |
| Other specified malignant tumors | 22 | 0.1 | 13 | 0.1 | 16 | 0.1 | 30 | 0.2 | 51 | 0.1 | 81 | 0.1 |
| Other unspecified malignant tumors | 708 | 4.7 | 456 | 3.4 | 661 | 4.8 | 1406 | 7.7 | 1825 | 4.3 | 3231 | 5.3 |
| Total | 15085 | 100.0 | 13611 | 100.0 | 13832 | 100.0 | 18194 | 100.0 | 42528 | 100.0 | 60722 | 100.0 |

WHAT THIS STUDY ADDS?

- Descriptive profile of 60,720 childhood cancer cases (0-19 years) in India from 96 hospitals between 2012-2019.

One of the main limitations of the present analysis was that cancer incidence rates could not be calculated since the data used was hospital-based. However, there is a wide belief that HBCRs could provide population-based statistics for childhood cancers since these are primarily treated at highly specialised hospitals. Therefore, it is vital to strengthen the HBCRs to obtain robust data which may be achieved by increasing the number of HBCRs (as has been steadily happening) and ensuring that data capture in each hospital is not limited to one department. By providing patient registration from all relevant departments within the hospital, including pathology and radiology, the case ascertainment can be close to complete.

Future efforts should include strengthening the existing childhood component of the HBCRs. A robust childhood cancer policy would augment better allocation of resources for the overall growth and survival of children.

Ethics clearance: Institutional Ethics Committee, ICMR-NCDIR; No.NCDIR/IEC/2017/5, dated March 1, 2017.

Contributors: GK, RSA, VR, AN, PM (Dr Payal), SLC, VPG, SD: Writing of the manuscript. TR and SKL: Analyzed and interpreted the data. PM (Dr Prashant): Conceptualization, writing, reviewing, and editing of the manuscript and overall project supervision. All authors read and approved the final manuscript.

Funding: The cancer registries are funded by intramural funding of ICMR-NCDIR and the Ministry of Health and Family Welfare, Government of India; *Competing interests:* None stated.

REFERENCES

1. World Health Organization. National Cancer Control Programmes: Policies and Managerial Guidelines. World Health Organization; 2002. Accessed May 2, 2022. Available from: <https://apps.who.int/iris/handle/10665/42494>
2. ICMR-NCDIR. Clinicopathological Profile of cancers in India: a report of the hospital based cancer registries, 2021. Accessed March 27, 2023. Available from: https://ncdirindia.org/all_reports/hbcr_2021/
3. Malhotra RK, Manoharan N, Nair O, et al. Patterns and trends of childhood cancer incidence (0-14 years) in Delhi, India: 1990-2014. *Indian Pediatr.* 2021;58:430-5.
4. Swaminathan R, Rama R, Shanta V. Childhood cancers in Chennai, India, 1990-2001: incidence and survival. *International J Cancer.* 2008;122:2607-11
5. Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. *Lancet Oncol.* 2020;21:e185-224
6. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed, 1st revision. World Health Organization; 2013.
7. World Health Organization ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth revision, 2nd ed. Geneva: World Health Organization; 2004.
8. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer.* 2005;103:1457-67.
9. Piñeros M, Mery L, Soerjomataram I, Bray F, Steliarova-Foucher E. Scaling up the surveillance of childhood cancer: a global roadmap. *J National Cancer Inst.* 2021;113:9-15.
10. Gupta V, Kalraiya A, Mekle D. Spectrum of pediatric malignancy- A cancer hospital-based study. *Pediatric Review: Int J Pediatr Res.* 2020;7:27-31.
11. Mulatsih S, Hariningrum A, Purwanto I, Oktasari R. Implementing Yogyakarta pediatric cancer registry for 16 years. *Pediatrica Indonesiana.* 2019;59:188-9412.
12. Bhopal SS, Mann KD, Pearce MS. Registration of cancer in girls remains lower than expected in countries with low/middle incomes and low female education rates. *Br J Cancer.* 2012;107:183-8.
13. Bhatia KP, Ganguly S, Sasi A, et al. Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis. *Lancet Oncol* 2022;24:54-63.
14. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol.* 2017;18:719-31.
15. Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. *Rambam Maimonides Med J.* 2014; 5:e0038.